Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

AbelZeta Says CAR-T Shows Efficacy in Hepatocellular Carcinoma Patients

publication date: Jun 5, 2024

AbelZeta Pharma, a Maryland-Shanghai CAR-T company, reported positive results from a China Investigator-Initiated Trial of C-CAR031 in patients with heavily pretreated advanced hepatocellular carcinoma (HCC). The study showed early signs of efficacy in the patients and a manageable safety profile. C-CAR031 is an autologous, armored GPC3-targeting CAR-T therapy being developed in China, though it belongs to AstraZeneca and is based on Astra-Zeneca’s novel GPC3-targeting CAR-T platform. It is manufactured by AbelZeta in China, where it being co-developed by AbelZeta and AstraZeneca. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here